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provided the new scoring system based on number of organs
involved, severity, and functional disability.
The following decade passed quickly. What did weThe majority of us entered the ﬁeld of allogeneic he-
matopoietic cell transplantation (HCT) to cure hematologic
cancersdby means of immunotherapy. Although this goal
has come closer and, with the expansion of transplantation
to more high-risk patients, it often seems a miraculous suc-
cess, chronic graft-versus-host disease (GVHD) has increas-
ingly become the major barrier preventing patients from
resuming their normal lives. Unfavorable trends in incidence
and severity of chronic GVHD have been observed overall,
despite better supportive care and advances in trans-
plantation practice [1]. In 2004, the National Institutes of
Health (NIH) summoned stakeholders in the ﬁeld and initi-
ated the Consensus Development Project on Criteria for
Clinical Trials in Chronic GVHD. The primary impetus for this
effort was to establish common terminology and best prac-
tices for clinical trials and biomarker studies to advance the
chronic GVHD ﬁeld and development of new therapies. The
ﬁrst consensus conference took place in Bethesda in June
2005. This project produced 6 original publications, which
were published in the Biology of Blood and Marrow Trans-
plantation, cited in peer-reviewed literature more than 1650
times since, and generated more than 35,000 visits to the
journal’s web site [2-7]. One half of those citations referred to
the article on diagnosis and staging by Filipovich et al. [2]
that deﬁned the new conceptual understanding of chronicaccomplish as a community since 2005, and did the NIH
chronic GVHD criteria affect clinical research and generate
research momentum? Are we any closer today to the goal of
eliminating chronic GVHD-related suffering in patients cured
by allogeneic HCT? The reality is that we still have no US
Food and Drug Administrationeapproved agent with an
indication for chronic GVHD treatment or prevention. Today,
the standard initial treatment with steroids is profoundly
frustrating because of the 50% failure rate of front-line ste-
roid therapy and the signiﬁcant toxicity of steroids. Second-
line therapy, and beyond, is still a laundry list of possible
options without biological or clinical indicators to tailor
therapy. Preventive and preemptive strategies to decrease
incidence and severity of chronic GVHD are in their infancy.
And our understanding of the basic immunobiology that
drives this autoimmune transplantation-related complica-
tion is profoundly incomplete.
So what has changed? First of all, the ﬁeld is much better
organized. We are speaking the same and more understand-
able language, which fosters new clinical, translational, and
basic collaborations. The newly formed NIH-funded US
chronic GVHD consortium, the German-Austrian-Swiss GVHD
consortium, and several single centers produced the ﬁrst
prospective cohort studies enrolling more than 2000 patients
using the new consensus criteria. These studies provided ev-
idence of the validity of the Consensus-recommended diag-
nostic and scoring system and measures for patient-reported
outcomes. Some studies collected clinical samples for immu-
nobiologic studies. There is also substantial national and in-
ternational support for use of the Consensus criteria in routine
clinical practice [8]. The time has come to reconvene, assess
the accomplishments and shortcomings, and use the data
generated over the last decade, instead of expert opinion, to
reﬁne the recommendations [9].
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Consensus conference was approved, thanks to major fund-
ing support provided by the National Cancer Institute, Center
for Cancer Research, and the Ofﬁce of Rare Diseases Research,
National Center for Advancing Translational Sciences. The
original 6 working groups reconvened with a major inﬂux of
new and junior investigators representing all facets of the
national and international HCT community, including
academia, government, regulatory agencies, industry, pro-
fessional societies, and advocacy groups. This time, a sepa-
rate task force was also formed speciﬁcally to address the
new directions in studying and hopefully decoding chronic
GVHD biology. Through the assistance of the Meredith
Cowden GVHD Foundation, the ﬁrst in-person planning
meeting was held in November 2013 in Cleveland, Ohio in
conjunction with the Fourth National GVHD Symposium.
Frequent conference calls of all working groups ensued, and
documents were prepared for the 2014 conference, held on
June 17 at the new National Cancer Institute facility at Shady
Grove, Gaithersburg, Maryland. The conferencewas attended
by 250 participants. All 6 working group drafts were avail-
able on the web site for public comments until August 15,
2014. Such productive collaboration was the result of dedi-
cated effort by the chairs and all working group participants.
The organizers also wish to thank all participants as well as
the funding agencies for their support and dedication to this
project.
The ﬁrst of the 6 2014 working group reports, the diag-
nosis and staging recommendations, is appearing in this
issue of the Biology of Blood and Marrow Transplantation [10].
Five others will follow in monthly succession, providing
updates in the areas of histopathology, biomarkers, response
criteria, ancillary and supportive care, and design of clinical
trials. All group documents have been revised and clariﬁca-
tions provided based on the accumulated interim data and
questions that emerged through use of the 2005 guidelines
[9]. The diagnosis and staging framework has been main-
tained, though organ scoring scales have been reﬁned. The
histopathology document provides important interim up-
dates and expanded discussion on entities such as lung and
kidney manifestations. The biomarkers manuscript has been
revised, and, although there is still no proven biomarker for
clinical use in chronic GVHD, a number of candidates exist.
The manuscript is updated with the new Food and Drug
Administration nomenclature and provides guidance for
biomarkers clinical development. The response criteria
manuscript provides a simpliﬁed and more practical frame-
work for use in trials based on the studies examining the
feasibility, reliability, and validity of the original 2005
criteria. The ancillary and supportive care document is sub-
stantially updated. Finally, although the clinical trials docu-
ment leaves much of the original 2005 paper intact, it
expands the deﬁnitions of eligibility, selection of endpoints,
deﬁnition of clinical beneﬁt, and charts potential develop-
mental paths for regulatory agencies’ approval as a critical
step in new drug development.In summary, we are convinced that the ﬁeld of chronic
GVHD is now poised to capitalize on the advances made
over last 10 years. The momentum generated by the ﬁrst
consensus meeting has resulted in unprecedented progress
in chronic GVHD. We believe that the second NIH consensus
effort will be remembered as an important endeavor that
was the turning point in our understanding and ability to
control chronic GVHD, this ﬁnal major impediment to full
recovery from allogeneic transplantation. Credit goes to
many, but our patients reap the beneﬁts.ACKNOWLEDGMENTS
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